Visceral obesity and metabolic syndrome

Obesity Reviews

Volumn 1, Issue 1, 2000, Pages 47-56

  Bosello, O ^a   Zamboni, M ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Cardiovascular risk factors; Metabolic syndrome; Obesity; Visceral fat

Indexed keywords

FATTY ACID;

ADIPOSE TISSUE; BODY COMPOSITION; BODY CONSTITUTION; GLUCOSE INTOLERANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; METABOLISM; OBESITY; REVIEW; VISCERA;

ADIPOSE TISSUE; BODY COMPOSITION; BODY CONSTITUTION; FATTY ACIDS, NONESTERIFIED; GLUCOSE INTOLERANCE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; VISCERA;

EID: 0034179765     PISSN: 14677881     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1467-789x.2000.00008.x     Document Type: Article

References (72)

1. Alberti KGMM, Zimmet PZ. for the WHO consultation Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1988; 13: 539-553.
2. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999; 83: 25F-29F.
3. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. 1956. Obes Res 1996; 4: 204-212.
4. Lean M. Clinical Handbook of weight management. Marin Dunitz, London 1998.
5. Després JP. Visceral obesity, insulin resistance, and dyslipidemia: contribution of endurance exercise training to the treatment of the plurimetabolic syndrome. Exerc Sport Sci Rev 1997; 25: 271-300.
6. Reaven GM. Role of insulin resistance in human diseases. Diabetes 1988; 37: 1595-1607.
7. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993; 44: 121-131.
8. De Fronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
9. Kaplan NM. Insulin resistance syndrome, two too many. Am J Cardiol 1992; 69: 1643-1644.
10. Suzuki M, Ikebuchi M, Shinozaki K, Hara Y, Tsushima M, Matsuyama T, Harano Y. Mechanism and clinical implication of insulin resistance syndrome. Diabetes 1996; 45: S52-S54.
11. Chisholm DJ, Campbell LV, Kraegen EW. Pathogenesis of the insulin resistance syndrome (syndrome X). Clin Exp Pharmacol Physiol 1997; 24: 782-784.
12. Haffner SM. Progress in population analyses of the insulin resistance syndrome. Ann N Y Acad Sci 1997; 827: 1-12.
13. Opara JU, Levine JH. The deadly quartet - the insulin resistance syndrome. South Med J 1997; 90: 1162-1168.
14. Beck-Nielsen H. General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the study of Insulin Resistance (EGIR). Drugs 1999; 58: 7-10.
15. Chen W, Srinivasan SR, Elkasabany A, Berenson GS. The association of cardiovascular risk factor clustering related to insulin resistance syndrome (Syndrome X) between young parents and their offspring: the Bogalusa Heart Study. Atherosclerosis 1999; 145: 197-205.
16. Greenlund KJ, Valdez R, Casper ML, Rith-Najarian S, Croft JB. Prevalence and correlates of the insulin resistance syndrome among Native Americans. The Inter-Tribal Heart Project. Diabetes Care 1999; 22: 441-447.
17. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders: The Bruneck Study. Diabetes 1998; 47: 1643-1649.
18. Chowdhury B, Sjöström L, Alpsten M, Kostanty J, Kvist H, Löfgren RA. multicompartment body composition tecnique based on computerized tomography. Intern J Obes 1994; 18: 219-234.
19. Rice CL, Cunningham DA, Paterson DH, Lefcoe MS. Arm and leg composition determined by computed tomography in young and elderly men. Clin Physiol 1989; 9: 207-220.
20. Zamboni M, Armellini F, Harris T, Turcato E, Micciolo R. Bergamo-Andreis IA, Bosello O Effects of age on body fat distribution and cardiovascular risk factors in women. Am J Clin Nutr 1997; 66: 111-115.
21. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. World Health Organisation: Geneva, 1997.
22. NIH-NHLBI. Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. The evidence report. Bethesda: MD, 1998.
23. Andres R. Mortality and obesity: the rationale for age-specific height-weight tables. In: Hazzard WR, Bierman EL, Blass JP, Ettinger WH Jr, Halter JB (eds). Principles of Geriatric Medicine and Gerontology, McGraw-Hill Publishers: NewYork, 1994, pp 847-853.
24. Willett WC, Manson JA, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, Hennekens CH. Weight, weight change and coronary heart disease in women. JAMA 1995; 273: 461-465.
25. Willet WC, Dietz WH, Colditz GA. Guidelines for healthy weight. New Engl J Med 1999; 341: 427-434.
26. Bosello O, Zamboni M, Armellini F, Todesco T. Biological and clinical aspects of regional body fat distribution. Diab Nutr Metab 1993; 6: 163-171.
27. Bjorntorp P. Obesity. Lancet 1997; 350: 423-426.
28. Bray GA. Obesity: A Time Bomb Be Defused. Lancet 1998; 352: 160-161.
29. Carey DG. Abdominal obesity. Curr Opin Lipidol 1998; 9: 35-40.
30. Després JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients' risk. Obes Res 1998; 6: 8S-17S.
31. Folsom AR, Kaye SA, Sellers TA, Hong CP, Cerhan JR, Potter JD, Prineas RJ. Body fat distribution and 5-year risk of death in older women. JAMA 1993; 269: 483-487.
32. Kissebah AH. Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease? Diabetes Res Clin Pract 1996; 30: 25-30.
33. Kohrt WM. Abdominal obesity and associated cardiovascular comorbidities in the elderly. Coron Artery Dis 1998; 9: 489-494.
34. Lamarche B. Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron Artery Dis 1998; 9: 473-481.
35. Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Kotani K, Tokunaga K. Pathophysiology and pathogenesis of visceral fat obesity. Obes Res 1995; 3: 187S-194S.
36. Must A, Spadano J, Coackley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-1529.
37. Zamboni M, Armellini F, Cominacini L, Turcato E, Todesco T, Bissoli L, Micciolo R, Bergamo-Andreis IA, Bosello O. Obesity and regional body fat distribution in men: separate and joint relationships to glucose tolerance and plasma lipoproteins. Am J Clin Nutr 1994; 60: 682-686.
38. Zamboni M, Armellini F, Sheiban I, De Marchi M, Todesco T, Bergamo Andreis IA. Cominacini l., Bosello o. Relation of body fat distribution in men and degree of coronary narrowings in coronary artery disease. Am J Cardiol 1992; 70: 1135-1138.
39. Pouliot MC, Després J-P, Lemieux S, Moorjani MS, Bouchard C, Tremblay A, Nadeau A, Lupien MPJ, Waist Circumference, Abdominal Sagittal Diameter. Best Simple Anthropometric Indexes of Abdominal Visceral Adipose Tissue Accumulation and Related Cardiovascular Risk in Men and Women. Am J Cardiol 1994; 73: 460-468.
40. Han TS, van Leer EM, Seidell JC, Lean MEJ. Waist Circumference action levels in the identification of cardiovascular risk factos: prevalence study in a random sample. BMJ 1995; 311: 1401-1405.
41. Saleh J, Sniderman AD, Cianflone K. Regulation of Plasma fatty acid metabolism. Clin Chim Acta 1999; 286: 163-180.
42. Smith U, Hammastern J, Bjorntorp P, Kral J. Regional differences and effect of weight reduction on human fat cell metabolism. Eur J Ciln Invest 1979; 9: 327-334.
43. Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of Body Fat Distribution on Free Fatty Acid Metabolism in Obesity. J Clin Invest 1989; 83: 1168-1173.
44. Barzilai N, She L, Liu BQ, Vuguin P, Cohen P, Wang J, Rossetti L. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999; 48: 94-98.
45. Kelley DE, Slasky BS, Janosky J. Skeletal muscle density: effect of obesity and non-insulin-dependent diabetes. Mellitus Am J Clin Nutr 1991; 54: 509-515.
46. Colberg SR, Simoneau JA, Thaete FL, Kelley DE. Skeletal muscle utilization of free fatty acids in women with visceral obesity. J Clin Invest 1995; 95: 1846-1853.
47. Vettor R, Zarjevski N, Cusin I, Rohner-Jeanrenaud F, Jeanrenaud B. Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats. Diabetologia 1994; 37: 1202-1208.
48. Simoneau J-A, Colberg SR, Thaete FL, Kelley DE. Skeletal muscle glycolytic and oxidative enzyme capacities are determinants of insulin sensitivity and muscle composition in obese women. FASEB J 1995; 9: 273-278.
49. Ferrannini E, Barret EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983; 72: 1737-1747.
50. Nuutila P, Koivisto VA, Knuuti J, Ruotsalainen U, Teräs M, Haaparanta M, Bergman J, Solin O, Voipio-Pulkki L-M, Wegellus U et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscel in vivo. J Clin Invest 1992; 89: 1767-1774.
51. Ferranini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. J Clin Invest 1997; 100: 1166-1173.
52. Ohlson LO, Larsson B, Svardsudd K, Welin L, Eriksson H, Wilhelmsen L, Bjorntorp P, Tibblin G. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years follow-up participants study men born in 1913. Diabetes 1985; 34: 1055-1058.
53. Peiris AN, Mueller RA, Smith GA, Struve MF, Kissebah AH. Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest 1986; 78: 1648-1657.
54. Cuotinho M, Wang Y, Gerstein HC, Yusuf S. The relationship between glucose and incident cardiovascular events. A Metaregression Analysis of Published Data from 20 Studies of 95,783 Individuals Followed for 12,4 Years. Diabetes Care 1999; 22: 233-240.
55. Anderson KM, Wilson PWF, Garrison RJ, Castelli WP. Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample: The Framingham offspring study. Atherosclerosis 1987; 68: 59-66.
56. Gray RS, Robbins DC, Wang W, Yeh JL, Fabsitz RR, Cowan LD, Welty TK, Lee ET. Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. Arterioscler Thromb Vasc Biol 1997; 17: 2713-2720.
57. Tchernof A, Lamarche B, Prud'Homme D, Nadeau A, Moorjani S, Labrie F, Lupien PJ, Després JP. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996; 19: 629-637.
58. Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999; 25: 199-211.
59. Austin MA, Selby JVLDL. subclass phenotypes and the risk factors of the insulin resistance syndrome. Int J Obes Relat Metab Disord 1995; 19: S22-S26.
60. Wannamethee SG, Shaper AG, Durrington PN, Perry IJ. Hypertension, serum insulin, obesity and the metabolic syndrome. J Hum Hypertens 1998; 12: 735-741.
61. Neel JV, Julius S, Weder A, Yamada M, Kardia SL, Haviland MB. Syndrome X: is it for real? Genet Epidemiol 1998; 15: 19-32.
62. Osei K. Insulin resistance and systemic hypertension. Am J Cardiol 1999; 84(1A): 33J-36J.
63. Maison P, Byrne CD, Hales CN, Wareham NJ. Hypertension and its treatment influence changes in fasting nonesterified fatty-acid concentrations: a link between the sympathetic nervous system and the metabolic syndrome? Metabolism 2000; 49: 81-87.
64. Miller GJ. Lipoproteins and the haemostatic system in atherothrombotic disorders. Baillieres Clin Haematol 1994; 7: 713-732.
65. Lindahl B, Asplund K, Eliasson M, Evrin P-E. Insulin resistance syndrome and fibrinolytic activity: the northern Sweden MONICA study. Int J Epidemiol 1996; 25: 291-299.
66. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-660.
67. Juhan-Vague I, Morange P, Renucci JF, Alessi MC. Fibrinogen, obesity and insulin resistance. Blood Coagul Fibrinolysis 1999; 10: S25-S28.
68. Colditz AG, Willet WC, Rotnitzky A, Manson JO. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Int Med 1995; 122: 481-486.
69. Everson SA, Goldberg DE, Helmrich SP, Lakka TA, Lynch JW, Kaplan GA, Salonen JT. Weight gain and the risk of developing insulin resistance syndrome. Diabetes Care 1998; 21: 1637-1643.
70. Vanhala MJ, Kumpusalo EA, Pitkajarvi TK, Takala JK. Metabolic syndrome in a middle-aged Finnish population. J Cardiovasc Risk 1997; 4: 291-295.
71. Vanhala MJ, Pitkajarvi TK, Kumpusalo EA, Takala JK. Obesity type and clustering of insulin resistance-associated cardiovascular risk factors in middle-aged men and women. Int J Obes 1998; 22: 369-374.
72. Kalff KG, Maya-Pelzer P, Andexer A, Deuber HJ. Prevalence of the metabolic syndrome in military and civilian flying personnel. Aviat Space Environ Med 1999; 70: 1223-1226.